MiNK Therapeutics, Inc.
General ticker "INKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $56.5M (TTM average)
MiNK Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -17.5%.
Estimated limits based on current volatility of 3.0%: low 10.68$, high 11.33$
Factors to consider:
- Total employees count: 23 (-25.8%) as of 2024
- Top business risk factors: Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Manufacturing risks, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.29$, 21.06$]
- 2026-12-31 to 2027-12-31 estimated range: [5.20$, 15.87$]
Financial Metrics affecting the INKT estimates:
- Positive: with PPE of -4.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Negative: negative Industry operating income (median)
Short-term INKT quotes
Long-term INKT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $22.92MM | $11.29MM | $12.64MM |
| Operating Income | $-22.92MM | $-11.29MM | $-12.64MM |
| Non-Operating Income | $0.46MM | $0.50MM | $0.15MM |
| R&D Expense | $15.49MM | $6.34MM | $5.76MM |
| Income(Loss) | $-22.46MM | $-10.78MM | $-12.49MM |
| Net Income(Loss)* | $-22.46MM | $-10.78MM | $-12.49MM |
| Stockholders Equity | $-18.06MM | $-19.59MM | $-14.23MM |
| Assets | $4.55MM | $5.72MM | $14.24MM |
| Operating Cash Flow | $-15.76MM | $-9.56MM | $-5.93MM |
| Capital expenditure | $0.07MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.07MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $-0.41MM | $10.82MM | $14.72MM |
| Earnings Per Share** | $-6.54 | $-2.88 | $-2.93 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.